Compare CWT & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | ALVO |
|---|---|---|
| Founded | 1926 | 2013 |
| Country | United States | Luxembourg |
| Employees | 1105 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 1.0B |
| IPO Year | 1997 | 2021 |
| Metric | CWT | ALVO |
|---|---|---|
| Price | $48.22 | $5.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $55.00 | $8.00 |
| AVG Volume (30 Days) | 470.5K | ★ 973.6K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $963,695,000.00 | N/A |
| Revenue This Year | $10.18 | $13.28 |
| Revenue Next Year | $5.81 | $18.63 |
| P/E Ratio | $48.94 | ★ $18.20 |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $41.29 | $2.94 |
| 52 Week High | $53.82 | $9.25 |
| Indicator | CWT | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 70.45 |
| Support Level | $42.31 | $3.10 |
| Resistance Level | $50.97 | $5.44 |
| Average True Range (ATR) | 0.85 | 0.26 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 0.44 | 78.70 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.